Tissue Regenix Group PLC product line-up highlights strength says CEO

Published on 13th Oct 2016

A raft of products just launched or soon to has put Tissue Regenix in very good shape, chief executive Antony Odell told Proactive Investors.
The Leeds-based regenerative med-tech group has seen US sales of its skin graft product Dermapure double while first European revenues beckon in 2017.
Its tendon replacement, Orthopure XT, launches in Germany next year while the company will present what Odell describes as outstanding data from its cardiac valve studies at the World Pediatric Congress in a few weeks time.
“In a number of different areas (cardiac, orthopaedics and woundcare) the platform is working extremely well,.” he told Proactive.

Pharma & Biotech
Add to favorites
Share with:

Related Videos

Latest

Media & Publishing
EU response to Brexit is most important, says City Index's Brooks

EU response to Brexit is most important, says City Index's Brooks

Published on 29th Mar 2017
Media & Publishing
'Don't panic about Brexit', says investment director at Architas

'Don't panic about Brexit', says investment director at Architas

Published on 29th Mar 2017

Recommended videos

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082.
You can contact us here.

Choose Proactive Region: